ROLE OF SYSTEMIC OMALIZUMAB IN MANAGEMENT OF ALLERGIC FUNGAL RHINOSINUSITIS

Badr Eldin Mostafa, Mohammed A. Hassan, Tarek Hamdi, Anas Askoura and Michael Mounir

ABSTRACT:

**Background:** Allergic fungal rhinosinusitis (AFRS) is due to the continuous exposure of fungal antigens to an atopic individual. It is caused by type I, IgE mediated (and possibly type III) hypersensitivity reaction to an extramucosal fungal antigen. Medical treatment following the surgery is the standard protocol of management. Steroids (systemic/topical) have been considered as the standard medical treatment for control of the disease despite high recurrence rate and their serious side effects. Instead, omalizumab, a humanized monoclonal anti-IgE antibody, can be tried as a new treatment modality with less side effects to control symptoms and decrease the recurrence rate in AFRS patients. It acts by aborting the immunological reaction to sinonasal fungi through preventing the release of inflammatory mediators that cause allergic signs and symptoms.

**Aim:** To evaluate the role of omalizumab for postoperative management of AFRS patients in comparison to topical steroids as regarding symptom free interval and side effects.

**Patients and methods:** A total of 20 patients with AFRS were included in the study. Patients were divided randomly into two equal groups: group A used local steroid and group B used single dose of subcutaneous omalizumab. Clinical parameters were compared at 4, 8, 12 and 24 weeks.

**Results:** Although there was no statistical significant difference between both groups as regards endoscopic nasal examination post-treatment, patients of group B were statistically better as regards clinical and subjective parameters.

**Conclusion:** We suggest that omalizumab has more superior effect than local steroids in controlling nasal symptoms in AFRS patients despite the same endoscopic scores post-treatment. More well-designed large prospective randomized controlled trials to determine the effects and optimal dosage and duration of omalizumab therapy in patients with AFRS will be necessary.

**Keywords:** Nasal polyps, hypersensitivity, sinusitis, Aspergillosis, steroids, omalizumab, Anti-Immunoglobulin E.

INTRODUCTION:

Allergic fungal rhinosinusitis (AFRS) accounts for 5 to 10% of all cases of chronic rhinosinusitis (CRS) requiring surgery worldwide\(^1\). It is a disease found mainly in areas of high humidity \(^2,^3\). Due to its chronic nature, it represents high economic burden throughout the world\(^4\). The
pathophysiological basis of AFRS is associated with type I IgE-mediated allergic response to inhaled mold spores that are present in the environment in a predisposed person (and to a lesser extent type III response)[5].

Treatment of AFRS usually involves surgery in the form of endoscopic sinus surgery (ESS) in combination with medical therapies to control its chronic nature. However, the optimal medical regimen is still vague[6,7]. Medical therapy usually includes systemic corticosteroids, local steroids, antifungal agents and immunotherapy[8]. Oral corticosteroids are used usually to control symptoms, endoscopic and radiological nasal scores[9]. However, long-term oral corticosteroid use is problematic with serious side effects. This requires the presence of alternative options for disease control with minimal side effects such as metered dose topical corticosteroids[10,11]. However, the accessibility of the metered dose topical steroids to sinus mucosa can be difficult owing to the occlusion of surgically opened sinus ostia due to significant inflammation in AFRS[12,13].

There is a number of patients who are refractory to these treatments modalities (ranging from 10% to about 100% depending on the length of follow-up period), beside their serious side effects. Thus, the search for a salvage therapy continues[14]. Reduction of IgE level may have a potential benefit in patients refractory to other treatment modalities owing to blunting the immune response to nasal fungal infection[15,16,17]. Also, immunotherapy results in decrease need for oral steroid therapy in AFRS patients[18].

Omalizumab is a humanized monoclonal anti-IgE antibody that has been shown to be an effective adjuvant therapy in severe atopic asthma and allergic rhinitis[19]. It decreases free IgE levels by binding to free circulating IgE. This process inhibits the binding and cross linking of IgE to the high-affinity IgE receptors on surface of mast cells and basophils, thereby preventing the release of inflammatory mediators that cause allergic signs and symptoms[20].

THE AIM OF THE WORK:

The aim of the study is to evaluate the role of omalizumab for postoperative management of allergic fungal rhinosinusitis in comparison to topical steroids as regarding symptom free interval and side effects.

PATIENTS AND METHODS:

The present study is a two-arm prospective (Case-Control), randomized, single blind clinical trial among patients with allergic fungal rhinosinusitis presenting to Otorhinolaryngology Department, Ain Shams University Hospitals. It was conducted during the period from October 2017 to January 2019. This study has been approved by the ethical committee.

Inclusion criteria were as the following:

All cases with AFRS presenting during the study period with or without previous surgical intervention after failure of medical treatment in the form of systemic steroids (oral prednisolone 30 mg gradual tapering dose) for one month and local steroids for at least 2 months duration of therapy. The treatment was discontinued 3 weeks before conduction of the study.

Criteria for diagnosis of AFRS in this study are based on Bent and Kuhn's[21] diagnostic criteria of AFRS which are: type I hypersensitivity, nasal polyps, characteristic CT scan findings, positive fungal stain or culture and allergic mucin with no tissue invasion.

Exclusion criteria:

a) Cases with allergic non fungal rhinosinusitis. Cases with other forms
Role of systemic omalizumab in management of allergic fungal rhinosinusitis

of fungal rhinosinusitis (eg: invasive forms).

b) History of one of the following: Severe idiopathic anaphylactic reaction; prior exposure to omalizumab or immuno-therapy within the past 2 years; parasitic infection; history of perennial or vasomotor rhinitis; presence immunocompromised state; clinically significant ECG abnormality; pregnancy and lactation, and low platelet count.

The patients were randomly assigned to one of two groups:

1. Group A [Omalizumab group]: 10 patients to receive a single dose of omalizumab (Xolair ' Novartis) in the form of subcutaneous injection (150 mg single-dose vial with lyophilized, sterile powder for reconstitution). The dose regimen respects patient's body weight irrespective to patient's total IgE level. The injection was given two weeks postoperatively.

2. Group B (controls): 10 patients to receive local steroids nasal sprays (Budesonide or Mometasone Furoate, 2 sprays (100 mcg) in each nostril twice daily for six months). Treatment was also started 2 weeks postoperatively.

All patients were enrolled under the strict guidelines of the committees on clinical investigation and ethics guidelines and gave informed consent. All patients underwent the following:

1. History taking and examination includes endoscopic nasal examination.
   a. Sino-Nasal Outcome Test (SNOT-20) scoring.
   b. Total Nasal Symptom Score (TNSS).
2. Preoperative non contrast Computed Tomography "CT" of nose and paranasal sinus, 5 mm axial cuts and coronal reconstruction cuts). Scores of CT findings (The Lund-Mackay CT scores) were used [22].
3. Serum total IgE (IU/mL) level assessments by ELISA (Human IgE ELISA Kits, Life Span Bio Sciences, Inc. USA).
4. Surgery: All selected patients underwent endoscopic sinus surgery (ESS). Intraoperatively, disease staging was performed by the Philpott-Javer endoscopic staging for AFRS [23].
5. Histopathological examination of postoperative specimens: H&E stain and PAS fungal stain to diagnose non invasive fungal infection.

6. Follow up:
   Patients were followed at the end of four, eight, twelve and twenty four weeks post-treatment (six months). The following data were collected from the patients' charts:
   - Change in sinonasal symptoms before and after therapy.
   - Change in serum total IgE level.
   - Change in endoscopic mucosal disease before and after therapy.
   - Documented side effects from therapy within both groups.

RESULTS AND DATA ANALYSIS:

A total of 20 patients were enrolled in our study randomly divided into two equal groups. Description of the patients' data was as follow: Group A: there were 10 patients, 6 female and 4 males. The mean age was 24.6 ± 8.57 (16 - 41 years), and the majority of cases were newly diagnosed (80%). Group B: consisted of 10 patients, 5 females and 5 males. The mean age was 24.3 ± 7.24 (14 - 36 years), and the majority of cases were newly diagnosed too (70%). There was no significant difference between the two study groups as regards personal and medical data.
Preoperative and intraoperative assessment parameters show also no statistical significant difference between cases of the two study groups (Table 1).

Comparison between the two study groups as regarding postoperative assessment parameters after 24 weeks of treatment revealed a highly significant difference (p=0.001) between post-operative TNSS scores in group A (Mean 4.2 ± 1.14) and group B (Mean 7.9 ± 1.1). Also, there was a significant difference between post-operative SNOT-20 scores in group A (Mean = 12.9 ± 7.05) and group B (Mean = 30.7 ± 7.33) with p value equals 0.02.

There was no statistically significant difference between the two study groups as regarding postoperative total IgE level measured at 4 and 8 weeks. However, postoperative total IgE level measured at 12 weeks showed a significant difference (p = 0.02) between study group A (Mean = 295.8 ± 213.78) and study group B (Mean = 627.5 ± 300.27). After 24 weeks, there was no statistically significant difference again between the two study groups. No significant difference was found between the two study groups as regarding changes in the post-operative endoscopic Phillpott-Javer staging scores (p= 0.144) (table 2).

Table (1): Comparison between the 2 study groups as regards pre-operative and intraoperative assessment parameters

<table>
<thead>
<tr>
<th></th>
<th>Group A</th>
<th>Group B</th>
<th>P</th>
<th>Sig</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ±SD Median</td>
<td>IQR</td>
<td>Mean ±SD Median</td>
<td>IQR</td>
</tr>
<tr>
<td>Preoperative SNOT-20</td>
<td>67.1 ± 6.9</td>
<td>67.0 ± 6.2</td>
<td>73.0</td>
<td>63.1</td>
</tr>
<tr>
<td>Preoperative TNSS</td>
<td>11.2 ± 1.0</td>
<td>11.0 ± 1.0</td>
<td>12.0</td>
<td>10.6</td>
</tr>
<tr>
<td>Preoperative Lund-Mackay CT scores</td>
<td>19.6 ± 5.0</td>
<td>21.5 ± 18.0</td>
<td>23.0</td>
<td>18.2</td>
</tr>
<tr>
<td>Preoperative total IgE</td>
<td>926.1 ± 678.5</td>
<td>910.5 ± 358.0</td>
<td>1232.0</td>
<td>763.4</td>
</tr>
<tr>
<td>Intraoperative Phillpott-Javer staging</td>
<td>65.3 ± 16.0</td>
<td>72.5 ± 53.0</td>
<td>75.0</td>
<td>62.7</td>
</tr>
</tbody>
</table>

-IQR: Interquartile range, *Mann-Whitney Test, **Student t test

Table (2): Comparison between the 2 study groups as regarding postoperative assessment parameters after treatment

<table>
<thead>
<tr>
<th></th>
<th>Group A</th>
<th>Group B</th>
<th>P</th>
<th>Sig</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ±SD</td>
<td>Mean ±SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postoperative SNOT-20 scores</td>
<td>22.9 ± 7.05</td>
<td>30.7 ± 7.33</td>
<td>0.02**</td>
<td>S</td>
</tr>
<tr>
<td>Postoperative TNSS scores</td>
<td>4.2 ± 1.14</td>
<td>7.9 ± 1.10</td>
<td>0.001**</td>
<td>HS</td>
</tr>
<tr>
<td>Postoperative total IgE(4 weeks)</td>
<td>573.1 ± 338.28</td>
<td>676.0 ± 343.32</td>
<td>0.5</td>
<td>NS</td>
</tr>
<tr>
<td>Postoperative total IgE(8 weeks)</td>
<td>392.7 ± 245.74</td>
<td>660.0 ± 297.65</td>
<td>0.057</td>
<td>NS</td>
</tr>
<tr>
<td>Postoperative total IgE(12 weeks)</td>
<td>295.8 ± 213.78</td>
<td>627.5 ± 300.27</td>
<td>0.02*</td>
<td>S</td>
</tr>
<tr>
<td>Postoperative total IgE(24 weeks)</td>
<td>431.7 ± 291.59</td>
<td>644.1 ± 289.53</td>
<td>0.12*</td>
<td>NS</td>
</tr>
<tr>
<td>Postoperative Phillpott-Javer stage</td>
<td>19.4 ± 9.65</td>
<td>24.9 ± 9.71</td>
<td>0.1*</td>
<td>NS</td>
</tr>
</tbody>
</table>

*Mann-Whitney Test, **Student t test

As regarding side effects within group A: only one case complained of nasopharyngitis (10% complication rate). Within group B: one patient had crustations formation. Another patient complaint of epistaxis and a third patient had nasal burning sensation (complication rate 30%). There was no statistical significant differe-
Role of systemic omalizumab in management of allergic fungal rhinosinusitis

DISCUSSION:

Treatment of AFRS is controversial. Different treatment protocols have been used to overcome recurrences including both medical and surgical care[24,25]. AFRS may represent an immunologic, rather than an infectious disease process. That is why reduction of IgE level by immunotherapy may have a potential benefit in patients refractory to other treatment modalities [26,27].

In our study, all patients were treated by endoscopic sinus surgery under general anaesthesia. Postoperatively, these patients were divided randomly into two groups of 10 patients each with different treatment plan. Postoperative follow up was done at 4, 8, 12 and 24 weeks using the same preoperative parameters and scores (subjective questionnaires, radiological, endoscopic and laboratory scores).

Upon comparison between both groups postoperatively, group A patients were better than group B patients as regards the subjective parameters (TNSS scores and SNOT-20 scores) and symptoms. The improvement was mainly in the allergic symptoms such as sneezing, itching, nasal discharge which can be referred to the action of omalizumab in reducing total IgE level with subsequent reduction of mast cells degradation and release of inflammatory and allergic mediators responsible for allergic nasal symptoms.

Post-operative total IgE level measured at 12 weeks interval showed also a significant difference (p = 0.02) between study group A (Mean = 295.8 ± 213.78) and study group B (Mean = 627.5 ± 300.27). There was no statistically significant difference between the two study groups as regarding postoperative total IgE level measured at 4, 8, 24 weeks interval. This can be explained by understanding omalizumab pharmacokinetics and pharmacodynamics. Following subcutaneous administration, omalizumab is absorbed slowly, reaching peak serum concentrations after an average of 7–8 days, with a terminal half-life of 26 days[28]. Despite that, within our study, we found that omalizumab action on total IgE level in AFRS patients remained up to 12 weeks post-injection. After that, Total IgE level began to rise again till it reached the same level of group B patients. Gan et al. in their proposal found that total IgE levels were not reduced in all patients post omalizumab therapy. They hypothesize that the reason for this was because omalizumab binds to IgE without changing its physiologic production. Hence, the absolute levels would therefore not be expected to change[8]. There was no significant difference between the two study groups as regarding changes in the post-operative endoscopic Phillpott-Javer staging scores (p= 0.144).

In our series, we did not face serious side effects in both groups. There were a few limitations in our study. The number of patients involved in this study was small. We used a single dose of 150 mg omalizumab in our study irrespective to total IgE level. This allowed us to monitor the effect of a fixed dose of omalizumab on different total IgE levels. Finally, the optimal duration and dosage of omalizumab therapy for the treatment of AFRS have yet to be determined. Further studies are needed, however, this study is considered one of the very few randomized control trials testing the role of omalizumab in management of AFRS in comparison to a standard treatment modality (topical steroid).

Conclusion:

We suggest that omalizumab has more superior effect than local steroids in controlling nasal symptoms in AFRS patients despite the same endoscopic scores post-treatment. We also recommend further studies on omalizumab in AFRS, prolonged...
study periods for longer follow-up of patients in the future with determination of optimum dosage and duration of omalizumab therapy.

Acknowledgements:

This work was done in the Department of Otolaryngology in Ain Shams University, Egypt.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES:


دور أماليزوماب في علاج التهابات الجيوب الأنفية الفطرية التحسسي

الخلفية: يرجع التهاب الجيوب الأنفية الفطرية التحسسي إلى التعرض المستمر للمستضدات الفطرية للفرد التائي. يحدث تفاعل فرط الحساسية لمستقبلات الفطرية خارجية بسبب النوع الأول من الحساسية بوساطة IgE (وربما النوع الثالث).

يعتبر العلاج الطبي بعد الجراحة علاجًا بشكل طبيعي للالتهاب. تعتبر الاستيروئيدات الموضعية هي العلاج الطبيعي لقياسيا للسيطرة على التهاب الجيوب الأنفية الفطرية التحسسي. وبدلاً من ذلك يمكن تجربة أماليزوماب (وهو جسم مضاد م拙ADEK) كطريقة علاج جديدة مع آثار جانبية أقل للسيطرة على الالتهابات، وتقليل نسبة ارتفاع الالتهاب الجيوب الأنفية الفطرية التحسسي. وهو يعمل عن طريق إبطاء رد الفعل المناعي للفطريات الجيوبية والنفاسية من خلال منع إطلاق وسطاء التهابات التي تسبب علامات وأعراض التحسسية.

الهدف من البحث: تقييم دور أماليزوماب كعلاج مابعد العملية الجراحية لدى مرضى التهاب الجيوب الأنفية الفطرية التحسسي مقارنة بالاستيروئيدات الموضعية فيما يتعلق بالوقت الزمني للعلاج وقضايا الآلام والاعراض الجانبية.

المريض والطرق: تشمل الدراسة 20 مريضاً من مرضى التهاب الجيوب الأنفية الفطرية التحسسي. تم تقسيم المرضى عشوائياً إلى مجموعتين متساويتين: المجموعة (A) تستخدم مزيج موضعي للمستيروئيدات (B) تستخدم أماليزوماب المستضدات الفطرية (C) وجرعة جلدية من أماليزوماب تحت الجلد. وقد تم تقييم الأعراض والعلامات السريرية في بعض الأفراد باستخدام الاستبانس أون (1) شهرين.

النتائج: على الرغم من عدم وجود فرق ذات دلالة إحصائية بين المجموعتين فيما يتعلق ببعض الأعراض والعلامات السريرية، المجموعة (B) أظهرت تحسنًا أفضل من الناحية الإحصائية فيما يتعلق بالعلامات السريرية والشخصية.

الاستنتاج: نعتقد أن أماليزوماب المضاد له تأثير أكثر تفكيرًا من الاستيروئيدات الموضعية في التحكم في أعراض التهاب الجيوب الأنفية الفطرية التحسسي على الرغم من النتائج المتقدمة بالفحص بعد الجراحة. ومن الضروري إجراء مزيد من التجارب المختبرية ذات الشروط الكبيرة المصممة لزيادة تعدد الجرعات المثلى ومدة العلاج بالأماليزوماب لدى المرضى الذين يعانون من التهاب الجيوب الأنفية الفطرية التحسسي.